CAMP · XBRL financial data

Camp4 Therapeutics financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CAMP's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	—	year only	858	1,497	795	348*	1,294	1,779	1,899
Revenue from contracts with customers	0	—	858	1,497	795	—	—	—	—
Research and development	9,702	9,996*	10,146	10,343	9,356	8,357*	10,160	10,817	11,434
General and administrative	3,814	4,690*	3,812	4,182	4,596	4,767*	4,205	4,342	4,494
Total operating expenses	13,516	14,686*	13,958	14,525	14,446	13,124*	14,365	15,159	15,928
Operating income (loss)	(13,516)	(14,034)*	(13,100)	(13,028)	(13,651)	(12,776)*	(13,071)	(13,380)	(14,029)
Interest income	94	610*	588	453	423	710*	910	807	984
Other income (expense)	(62)	—	79	(12)	(71)	—	18	(27)	(99)
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0
Net income (loss)	(13,484)	(13,279)*	(12,433)	(12,587)	(15,099)	(40,284)*	(18,331)	(33,530)	(28,956)
Earnings per share, basic USD per share	(24.19)	—	(0.62)	(0.62)	(0.55)	—	(0.32)	(0.58)	(0.37)
Earnings per share, diluted USD per share	(24.19)	—	(0.62)	(0.62)	(0.55)	—	(0.32)	(0.58)	(0.37)
Weighted average shares, basic thousands of shares	557	—	20,153	20,160	27,275	—	57,924	57,930	78,946
Weighted average shares, diluted thousands of shares	557	—	20,153	20,160	27,275	—	57,924	57,930	78,946

Fiscal quarters (CAMP's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	2,528	64,039	49,323	39,052	75,255	109,517	99,209	86,398	124,522
Accounts receivable	1,000	—	—	—	—	—	—	—	—
Prepaid and other current assets	1,976	2,344	2,352	2,034	2,453	3,232	2,258	2,899	2,285
Total current assets	5,504	66,383	51,675	41,086	77,708	114,095	102,197	90,027	127,537
Property and equipment, net	—	3,858	3,603	3,407	2,895	—	—	—	—
Right-of-use asset	6,479	6,015	5,540	5,061	4,078	397	363	591	3,846
Total assets	21,364	78,307	62,773	51,275	86,395	117,808	105,457	93,428	134,013
Accounts payable	3,873	1,210	1,398	1,195	585	182	863	1,093	760
Accrued liabilities	3,677	4,833	1,838	2,870	4,065	5,632	4,302	4,237	6,979
Total current liabilities	11,829	9,598	6,441	7,335	7,903	15,514	16,624	19,142	19,865
Lease liability, non-current	6,274	5,493	4,700	3,892	3,046	1,688	1,738	1,570	4,825
Total liabilities	18,192	15,163	11,201	11,288	27,728	70,104	74,555	94,121	26,919
Accumulated deficit	(198,474)	(211,753)	(224,186)	(236,773)	(251,872)	(292,156)	(310,487)	(344,017)	(372,973)
Total stockholders' equity	(158,975)	63,144	51,572	39,987	58,667	47,704	30,902	(693)	107,094
Total liabilities and equity	21,364	78,307	62,773	51,275	86,395	117,808	105,457	93,428	134,013
Common shares outstanding (cover page) thousands of shares	20,161	20,161	20,161	20,161	46,881	51,919	51,926	62,753	62,754

Fiscal quarters (CAMP's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(13,484)	(13,279)*	(12,433)	(12,587)	(15,099)	(40,284)*	(18,331)	(33,530)	(28,956)
Stock-based compensation	1,593*	797*	861	1,002*	984*	1,151*	1,472	1,931*	2,024*
Depreciation and amortization	418*	418*	421	430*	416*	372*	520	515*	523*
Net cash from operating activities	(9,693)*	(11,288)*	(14,286)	(10,343)*	(11,217)*	6,293*	(10,981)	(12,686)*	(8,165)*
Purchases of property and equipment	0*	263*	279	0*	0*	0*	0	129*	740*
Net cash from investing activities	0*	(263)*	(279)	0*	36*	0*	0	(129)*	(740)*
Proceeds from issuing common stock	31*	76,320*	0	0*	28,961*	28,555*	—	—	—
Net cash from financing activities	(386)*	73,062*	(151)	72*	47,384*	28,585*	57	4*	47,029*
Net change in cash	(10,079)*	61,511*	(14,716)	(10,271)*	36,203*	34,878*	(10,924)	(12,811)*	38,124*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Camp4 Therapeutics	124,522	1,899	(8,165)*	62.8M	11.4 quarters	Q3 FY26 10-QSep 30, 2026
X4 Pharmaceuticals	185,801	2,879	(20,186)*	102.1M	9.2 quarters	Q3 FY26 10-QSep 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 5:57 PM ET. The filing on SEC.gov is the record.